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Background: Comparison of intracoronary infusion of bone marrow (BM)-derived
unselected mononuclear cells (MNC) and selected CD34+CXCR4+ cells (CXCR4) in
acute myocardial infarction (MI) and reduced <40% left ventricular ejection fraction
(LVEF) assessed by MRI.
Methods: Bone marrow was harvested from iliac crest. MNC were isolated by Ficoll
gradient and CD34+CXCR4+ by immunomagnetic selection. METHODS: 200 pa-
tients were randomized to intracoronary infusion of MNC (n¼80) or CD34CXCR4
(n¼80) BM cells or to the control (CTRL) without BM cell treatment. Primary end-
point: change of LVEF and volumes measured by MRI before and 6 months after the
procedure.
Results: Primary end-point: After 6 months LVEF increased by 3% (p¼0.01) in
MNC, 3% in CD34CXCR4 (p¼0.04) and remained unchanged in CTRL groups
(p¼0.73). There were no signiﬁcant differences in absolute changes of LVEF between
the groups. Absolute changes of LVESV and LVEDV were not signiﬁcantly different
in all groups. Signiﬁcant increase of LVEF was observed only in patients treated with
BM cells who had baseline LVEF < median (37%). Baseline LVEF < median and
time from the onset of symptoms to primary PCI  median were predictors of LVEF
improvement afterBMC therapy. There were no differences in MACE (death, rein-
farction, stroke, TVR) between groups at 6 months. After 6 years no differences in
death (Kaplan-Meyer, p¼0.82), MI (p¼ 0.445), death/MI/stroke (p¼0.914) and death/
MI/heart failure (p¼0.712) were found.
Conclusion: In patients with acute MI and impaired LVEF treatment with BM cells
does not lead to a signiﬁcant improvement of LVEF or volumes. There was a trend in
favor of cell therapy in patients with most severely impaired LVEF. Long term follow-
up conﬁrmed the safety of the cell therapy.
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Co-injection Basic Fibroblast Growth Factor for Adipose Derived Stem Cells
Transplantation: Improved Cardiac Remodelling and Function of Myocardial
Infarction
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Background: The cell-based therapy can improve the cardiac function but is limited
by the survival within the ischemic tissues. The injectable cardiac tissue engineering
aims to support cell-based therapies and enhance their efﬁcacy for cardiac diseases. So
far, no research is devoted to studying the usefulness of the combination ofbFGF and
adipose-derived stem cells (ADSCs) to treat myocardial infarction.
Methods: Adipose derived stem cells (ADSCs) were isolated from subcutaneous
adipose tissues. The ADSCs were induced to differentiate into adipocytes, osteoblasts,
and cardiac myocyte in vitro. bFGF was then co-injected with ADSCs into the
left ventricular wall of rat infarction models. The structure and functional conse-
quences of transplantation was determined by detailed histological analysis and
echocardiography.
Results: After injection four weeks later, graft size were signiﬁcantly higher and
larger in the bFGF + ADSCs group than the PBS + ADSCs group and PBS + bFGF
(p < 0.05). The ADSCs could differentiate into cardiomyocytes, endothelial cells and
vascular smooth muscle cells in vivo. The arteriole densities within the infarcted area
improved signiﬁcantly in the bFGF + ADSCs group compared with those in the PBS +
ADSCs group and PBS + bFGF4 weeks after transplantation (p < 0.05). In addition,
Quantitative analysis showed that the percentage of ﬁbrotic areas was signiﬁcantly
lower in PBS + ADSCs and bFGF + ADSCs groups than that in the PBS only group
and PBS + bFGF group (p < 0.05).
Conclusion: Combined use of bFGF and ADSCs transplantation may signiﬁcantly
increased the number of arterioles, reduced the infarcted size, attenuated ventricular
remodeling and improved cardiac function.S44 JACC Vol 63/12/Suppl S j April 22–TCTAP A-156
Retrograde Coronary Vein Delivery of Basic Fibroblast Growth Enhances Bone
Marrow Mesenchymal Stem Cells Engraftment for Myocardial Repair in a
Canine Infarct Model
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Xing-Xin Wu
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Background: Retrograde coronary venous delivery of basic ﬁbroblast growth factor
(bFGF) or bone marrow mesenchymal stem cells (MSCs) have been demonstrated to
target infarcted myocardium. The present study aimed to investigate the effects of
bFGF on MSCs engraftment via coronary vein infusion and their combined efﬁcacy
for myocardial repair in a canine model of myocardial infarction.
Methods: Under hypoxic conditions, the migration capacity was assessed in MSCs
cultured with bFGF, vascular endothelial growth factor or insulin-like growth factor.
For in vivo experiments, dogs underwent ligation of left anterior descending coronary
artery to create myocardial infarction (MI). After one week, combined bFGF (200 ng/
mL) and MSCs (1 s 108 cells) (n ¼ 5), MSCs alone (1 s 108 cells, n ¼ 5), bFGF
alone (200ng/mL, n ¼ 5), or placebo (phosphate-buffered saline, n ¼ 3) was retro-
gradely infused into anterior interventricular vein. Serial echocardiography studies
were performed at baseline, 1 week after MI (before infusion) and 4 weeks after
infusion. Then, hearts were harvested for histology analysis.
Results: The number of migrated cells was higher in MSCs cultured with bFGF
compared with other growth factors in vitro. Four weeks after treatment, left ventricular
ejection fractionwas signiﬁcantly better in the bFGF/MSCs andMSCs alone group (both
p< 0.05 versus control group). However, the radial strain value of the infarct border area
was improved only in the combination-treated group, accompanied by greater infarct size
reduction (p < 0.05). Immunoﬂuorescence showed that bFGF signiﬁcantly increased
retention of the enhanced green ﬂuorescence protein-labeled MSCs in the infarcted area,
with enhanced cell differentiation into myocardiocytes and vessels (all p < 0.05).
Conclusion: Retrograde coronary vein infusion of bFGF promotes MSCs engraftment
in the infarcted myocardium, accompanied by enhanced angiomyogenesis. Combi-
nation of bFGF with MSCs restores cardiac function and regional contractility, with
greater infarct size reduction. Our ﬁndings suggest a novel strategy for cardiac repair
after myocardial injury.
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Background: Cell transplantation has emerged as a promising treatment for cardiac
repair after myocardial infarction. However, efﬁcient cell delivery to the targeted
myocardium remains a practical challenge. This study evaluated the efﬁciency of
mesenchymal stem cells (MSCs) delivery via coronary veins and examined cell
engraftment and differentiation in a canine infarct model.
Methods: Dogs (n ¼ 12) underwent ligation of left anterior descending (LAD) cor-
onary artery to create myocardial infarction (MI). After one week, the coronary sinus
was cannulated and an over-the-wire balloon catheter was advanced to the mid-portion
of anterior interventricular vein (AIV) in parallel to LAD. The balloon catheter was
inﬂated temporarily to occlude the AIV, and 1 s 108 enhanced green ﬂuorescence
protein (EGFP)-labeled mesenchymal stem cells (MSCs) were injected into the AIV.
The animals were euthanized at 1 (n ¼ 4), 7 (n ¼ 4), and 14 (n ¼ 4) days post-
delivery. The hearts were harvested for histology analysis.
Results: Cell delivery by retrograde coronary venous perfusion was successful in
100% (12/12) of the animals. No death, cardiac tamponade, or sustained arrhythmia
events occurred during the procedure or the follow-up periods. The average number of
EGFP+ cells was dramatically higher in the LAD territory than in the remote left
circumﬂex territory at each timepoint (221  24 versus 15  6 cells/mm2 at 1 day, 306
 42 versus 16  5 cells/mm2 at 7 days, 262  24 versus 9  3 cells/mm2 at 14 days)
(all p<0.05). Notably, a more homogeneous distribution of EGFP+ cells was observed
in all slides of the LAD region. In addition, we found cardiac troponin I and a- smooth
muscle actin expression in EGFP+ cells, indicating the differentiation of MSCs into
cardiomyocytes and arterioles.
Conclusion: Regional cell delivery is safe and feasible through coronary venous
system. Infusion of MSCs via the coronary veins provides targeted and homogeneous
cell engraftment into the infarcted myocardium for cardiac repair.25, 2014 j TCTAP Abstracts/POSTER/Cell Therapy and Angiogenesis
